Tuesday, January 5, 2021

New York Times: "How the Oxford-AstraZeneca Vaccine Works"

"The University of Oxford partnered with the British-Swedish company AstraZeneca to develop and test a coronavirus vaccine known as ChAdOx1 nCoV-19 or AZD1222. A clinical trial revealed the vaccine was up to 90 percent effective, depending on the initial dosage. Despite some uncertainty over trial results, Britain authorized the vaccine for emergency use in December, and India authorized a version of the vaccine called Covishield on Jan. 3. "
Continue reading the article online (subscription may be required)

No comments:

Post a Comment